Cardiol Therapeutics Inc
CRDL0.995USD
+0.035+3.63%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
87.00MMarket Cap
LossP/E TTM
More Details of Cardiol Therapeutics Inc Company
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Cardiol Therapeutics Inc Info
Ticker SymbolCRDL
Company nameCardiol Therapeutics Inc
IPO dateDec 20, 2018
CEOElsley (David)
Number of employees18
Security typeOrdinary Share
Fiscal year-endDec 20
Address602-2265 Upper Middle Road East
CityOAKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeL6H 0G5
Phone12899100850
Websitehttps://www.cardiolrx.com/
Ticker SymbolCRDL
IPO dateDec 20, 2018
CEOElsley (David)
Company Executives of Cardiol Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Pekos
Mr. Peter Pekos
Independent Director
Independent Director
506.04K
+38750.00%
Mr. Colin George Stott
Mr. Colin George Stott
Independent Director
Independent Director
142.50K
--
Ms. Jennifer M. Chao
Ms. Jennifer M. Chao
Independent Director
Independent Director
133.33K
+13334.00%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
133.33K
+13334.00%
Mr. Bernard Lim
Mr. Bernard Lim
Chief Operating Officer
Chief Operating Officer
40.00K
+10000.00%
Mr. David Elsley
Mr. David Elsley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Guillermo Torre-Amione, M.D., Ph.D.
Dr. Guillermo Torre-Amione, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Waddick, CPA
Mr. Christopher (Chris) Waddick, CPA
Chief Financial Officer, Corporate Secretary, Director
Chief Financial Officer, Corporate Secretary, Director
--
--
Mr. Trevor Burns
Mr. Trevor Burns
Investor Relations
Investor Relations
--
--
Dr. Andrew Hamer
Dr. Andrew Hamer
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Pekos
Mr. Peter Pekos
Independent Director
Independent Director
506.04K
+38750.00%
Mr. Colin George Stott
Mr. Colin George Stott
Independent Director
Independent Director
142.50K
--
Ms. Jennifer M. Chao
Ms. Jennifer M. Chao
Independent Director
Independent Director
133.33K
+13334.00%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
133.33K
+13334.00%
Mr. Bernard Lim
Mr. Bernard Lim
Chief Operating Officer
Chief Operating Officer
40.00K
+10000.00%
Mr. David Elsley
Mr. David Elsley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MMCAP Asset Management
10.51%
Tejara Capital Ltd.
4.59%
Elsley (David G)
1.20%
Willner (Michael Jay)
0.78%
Hamer (Andrew Warwick M.D.)
0.60%
Other
82.31%
Shareholders
Shareholders
Proportion
MMCAP Asset Management
10.51%
Tejara Capital Ltd.
4.59%
Elsley (David G)
1.20%
Willner (Michael Jay)
0.78%
Hamer (Andrew Warwick M.D.)
0.60%
Other
82.31%
Shareholder Types
Shareholders
Proportion
Hedge Fund
11.30%
Investment Advisor
6.36%
Individual Investor
3.83%
Research Firm
1.17%
Investment Advisor/Hedge Fund
1.13%
Other
76.21%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
92
11.26M
7.89%
+2.50M
2025Q3
95
8.76M
9.94%
+1.81M
2025Q2
91
7.15M
12.37%
-1.34M
2025Q1
92
8.48M
12.02%
-1.45M
2024Q4
96
10.25M
12.83%
+2.50M
2024Q3
87
7.76M
12.86%
-212.53K
2024Q2
85
7.98M
16.50%
-894.54K
2024Q1
77
8.87M
15.73%
-1.98M
2023Q4
80
8.98M
16.88%
+542.22K
2023Q3
78
8.44M
17.40%
-315.18K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MMCAP Asset Management
293.06K
0.29%
--
--
Sep 30, 2025
Tejara Capital Ltd.
5.13M
5.16%
+2.50M
+95.05%
Oct 17, 2025
Elsley (David G)
1.34M
1.35%
+100.00K
+8.04%
Oct 17, 2025
Willner (Michael Jay)
866.59K
0.87%
+80.24K
+10.20%
Sep 06, 2024
Hamer (Andrew Warwick M.D.)
669.95K
0.67%
+133.33K
+24.85%
Oct 01, 2025
Global X Investments Canada Inc.
669.54K
0.67%
--
--
Nov 30, 2025
AdvisorShares Investments, LLC
557.39K
0.56%
-300.00K
-34.99%
Sep 30, 2025
BofA Global Research (US)
551.05K
0.55%
+524.60K
+1982.98%
Sep 30, 2025
Marshall Wace LLP
544.32K
0.55%
+544.32K
--
Sep 30, 2025
Pekos (Peter)
506.04K
0.51%
+38.75K
+8.29%
Apr 10, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Pure Cannabis ETF
1.32%
AdvisorShares Pure Cannabis ETF
Proportion1.32%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
